JP2002526522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002526522A5 JP2002526522A5 JP2000574496A JP2000574496A JP2002526522A5 JP 2002526522 A5 JP2002526522 A5 JP 2002526522A5 JP 2000574496 A JP2000574496 A JP 2000574496A JP 2000574496 A JP2000574496 A JP 2000574496A JP 2002526522 A5 JP2002526522 A5 JP 2002526522A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- aryl
- optionally
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 26
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- WUACDRFRFTWMHE-UHFFFAOYSA-N 3,4-diaminocyclobut-3-ene-1,2-dione Chemical class NC1=C(N)C(=O)C1=O WUACDRFRFTWMHE-UHFFFAOYSA-N 0.000 description 1
- DFSFLZCLKYZYRD-UHFFFAOYSA-N 3,4-diethoxycyclobut-3-ene-1,2-dione Chemical compound CCOC1=C(OCC)C(=O)C1=O DFSFLZCLKYZYRD-UHFFFAOYSA-N 0.000 description 1
- VFHRIIVWOBSOAE-UHFFFAOYSA-N 3-(3-bromoanilino)-4-ethoxycyclobut-3-ene-1,2-dione Chemical compound O=C1C(=O)C(OCC)=C1NC1=CC=CC(Br)=C1 VFHRIIVWOBSOAE-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK199801246 | 1998-10-02 | ||
| DKPA199801246 | 1998-10-02 | ||
| PCT/DK1999/000504 WO2000020378A1 (en) | 1998-10-02 | 1999-09-27 | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002526522A JP2002526522A (ja) | 2002-08-20 |
| JP2002526522A5 true JP2002526522A5 (enExample) | 2006-11-24 |
Family
ID=8102663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574496A Withdrawn JP2002526522A (ja) | 1998-10-02 | 1999-09-27 | ジアミノシクロブテン−３，４−ジオン誘導体、その製造方法及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6413996B2 (enExample) |
| EP (1) | EP1117633B1 (enExample) |
| JP (1) | JP2002526522A (enExample) |
| AT (1) | ATE224358T1 (enExample) |
| AU (1) | AU5727899A (enExample) |
| DE (1) | DE69903053T2 (enExample) |
| WO (1) | WO2000020378A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002303084B2 (en) * | 2001-02-02 | 2006-05-25 | Pharmacopiea, Inc. | 3,4-di-substituted cyclobutene-1, 2 -diones as CXC chemokine receptor antagonists |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| WO2003000245A1 (en) * | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| EP1434775A1 (en) | 2001-10-12 | 2004-07-07 | Schering Corporation | 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| NZ535314A (en) | 2002-03-18 | 2007-08-31 | Schering Corp | Combination treatments for chemokine-mediated diseases |
| ES2321186T3 (es) | 2002-10-09 | 2009-06-03 | Schering Corporation | Dioxidos de tiadiazol y monoxidos de tiadiazol como ligandos de los receptores de quimioquinas cxc y cc. |
| DE602004017175D1 (de) | 2003-06-17 | 2008-11-27 | Neurosearch As | Diphenylurea-derivative und ihre verwendung als chloridkanalblocker |
| MY139808A (en) | 2003-12-19 | 2009-10-30 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
| JP4851943B2 (ja) | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
| CN101253165A (zh) | 2005-06-29 | 2008-08-27 | 先灵公司 | 作为cxc－化学活素受体配体的二取代的二唑 |
| ATE486078T1 (de) | 2005-06-29 | 2010-11-15 | Schering Corp | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors |
| US9926275B2 (en) * | 2013-08-22 | 2018-03-27 | Northeastern University | Allosteric modulators of the cannabinoid 1 receptor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE68785T1 (de) * | 1985-07-31 | 1991-11-15 | Hoechst Ag | N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen. |
| US4889612A (en) | 1987-05-22 | 1989-12-26 | Abbott Laboratories | Ion-selective electrode having a non-metal sensing element |
| IL99246A0 (en) * | 1990-09-10 | 1992-07-15 | Abbott Lab | Angiotensin ii receptor antagonists and pharmaceutical compositions containing them |
| US5489612A (en) | 1991-08-23 | 1996-02-06 | The University Of Alabama At Birmingham Research Foundation | Calixarene chloride-channel blockers |
| US5212283A (en) * | 1992-03-03 | 1993-05-18 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Polyimides containing the cyclobutene-3, 4-dione moiety |
| US5273992A (en) | 1992-11-02 | 1993-12-28 | Beth Israel Hospital Assoc. Inc. | Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ |
| US5559151A (en) * | 1994-11-30 | 1996-09-24 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers |
| CA2255858C (en) * | 1996-05-24 | 2007-09-11 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
-
1999
- 1999-09-27 EP EP99944284A patent/EP1117633B1/en not_active Expired - Lifetime
- 1999-09-27 DE DE69903053T patent/DE69903053T2/de not_active Expired - Lifetime
- 1999-09-27 AT AT99944284T patent/ATE224358T1/de not_active IP Right Cessation
- 1999-09-27 AU AU57278/99A patent/AU5727899A/en not_active Abandoned
- 1999-09-27 JP JP2000574496A patent/JP2002526522A/ja not_active Withdrawn
- 1999-09-27 WO PCT/DK1999/000504 patent/WO2000020378A1/en not_active Ceased
-
2001
- 2001-03-08 US US09/801,344 patent/US6413996B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002526522A5 (enExample) | ||
| AU2014239995B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| CN105025898B (zh) | 组胺h4受体的苯并咪唑‑2‑基嘧啶调节剂 | |
| TWI428318B (zh) | 環烷基胺衍生物 | |
| TW200530195A (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
| JP2002525363A (ja) | インデノ−、ナフト−およびベンゾシクロヘプタジヒドロチアゾール誘導体、それらの製造ならびに食欲抑制薬としてのそれらの使用 | |
| RU2107062C1 (ru) | N-замещенные производные имидазола или их соли, способ их получения, промежуточное соединение и фармацевтическая композиция, являющаяся антагонистом ангиотенсина ii | |
| JP2004528385A5 (enExample) | ||
| US20230348441A1 (en) | Bicyclic compound that acts as crbn protein regulator | |
| JP2003528825A (ja) | ８ａ位で置換された８，８ａ−ジヒドロ−インデノ［１，２−ｄ］チアゾール誘導体、その製造方法及び医薬、例えば食欲抑制薬としてのその使用 | |
| JP5329656B2 (ja) | イミダゾリジン誘導体 | |
| TW201103893A (en) | New compounds | |
| JP4393376B2 (ja) | フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用 | |
| KR101266587B1 (ko) | 조직 인자 생성 억제제 | |
| CN101384595A (zh) | Cd80拮抗剂的盐 | |
| JP2002538148A (ja) | 多環２−アミノチアゾール系、その製造方法およびそれを含む医薬 | |
| US7799928B2 (en) | Process for the preparation of irbesartan hydrochloride | |
| HU195644B (en) | Process for producing new phenyl-acetonitril derivatives and pharmaceutical compositions containing them as active components | |
| DE69327029T2 (de) | 4,5,6,7-Tetrahydro-1H-imidazo 4,5-c pyridin-6-Carbonsäureamid Derivate als Angiotensin II Antagonisten | |
| TWI395581B (zh) | 二氫茚基化合物 | |
| WO2010113860A1 (ja) | ビフェニル－環状アミン化合物 | |
| JP2011102241A (ja) | 新規１−アミノカルボニルピペリジン誘導体 | |
| JP2006509022A5 (enExample) | ||
| JPH04330072A (ja) | ピリミジンジオン誘導体 | |
| WO1998014430A1 (en) | Pyrimidine derivatives |